Parexel, one of the world’s largest clinical research organisations (CROs), providing the full range of Phase I to IV clinical development services, has announced a multi-year strategic partnership with Palantir Technologies Inc. This collaboration marks a pivotal moment in the industry as Parexel becomes the first CRO to join forces with Palantir, a renowned builder of Artificial Intelligence (AI) systems.

The partnership aims to harness the power of AI to enhance and expedite the delivery of safe and effective clinical trials for biopharmaceutical customers worldwide. By leveraging Palantir’s Foundry and Artificial Intelligence Platform (AIP), Parexel seeks to bolster its clinical data platform, with a primary focus on enhancing trial efficiency while upholding the highest standards of safety and regulatory compliance.

Jonathan Shough, Chief Information Officer for Parexel, expressed excitement about the expanded collaboration, sharing, “We’re thrilled to expand our collaboration with Palantir — a leader in artificial intelligence technology — as we build on our application of AI to further improve clinical trial execution and advance our offerings in Real World Evidence, advanced analytics, and Health Outcomes. Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or in various stages of development that demonstrate our commitment to be a fully digital CRO.”

Parexel’s commitment to innovation is underscored by its Precision Pathway, an end-to-end operational approach prioritising timely data delivery, efficiency, quality, and predictability throughout the clinical trial lifecycle. Palantir’s industry-leading software further enhances Parexel’s clinical data platform, enabling hyper-automation of manual processes, promoting data discoverability, extracting insights from historical trials, and facilitating seamless collaboration among scientific and operational teams.

Stephen Pyke, DIC, Chief Clinical Data and Digital Officer for Parexel, highlighted the potential of AI to enhance data quality and streamline the clinical trial process, ultimately benefiting customers and patients alike. He shared, “Parexel is well-positioned to rapidly scale our use of AI to enhance data quality and streamline the clinical trial process to better deliver for our customers and patients. Combining our end-to-end delivery model with Palantir’s world-class security, governance, and Artificial Intelligence Platform will generate strategic insights to inform drug development and accelerate time to market.”

Dr. Lalarukh Haris Shaikh, Executive, Life Sciences at Palantir, commended Parexel’s commitment to digital transformation, emphasising the transformative power of generative AI, expressing, “Parexel has embraced the principles of digital transformation using generative AI at remarkable speed and scale. The company will significantly accelerate its business by untapping the value of data via an ontology constructed within Palantir Foundry and connecting it to the immense power of generative AI in AIP. We are delighted to deepen our exceptional collaboration with Parexel, empowering them to fully leverage the capabilities of AIP and Foundry throughout their clinical processes and business operations.”

This collaboration between Parexel and Palantir heralds a new era of innovation in clinical trial data management, promising to drive efficiency, quality, and safety in the pursuit of improved patient outcomes.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.